Molecular Genetics and Metabolism Reports

Papers
(The TQCC of Molecular Genetics and Metabolism Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy18
Allan-Herndon-Dudley syndrome in a female patient and related mechanisms17
Rapid genotyping of inversion variants in Mucopolysaccharidosis type II using long-range PCR: A case report16
Compound heterozygote variants: c.848A > G; p.Glu283Gly and c.890C > T; p.Ala297Val, of Isovaleric acid-CoA dehydrogenase (IVD) gene causing severe Isovaleric acidemia with hyperammonemia14
Corrigendum to “Evaluation of 3-O-methyldopa as a biomarker for aromatic L-amino acid decarboxylase deficiency in 7 Brazilian cases” [27/100744/2021/ pages: 1-4]13
Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria12
A novel, high throughput, and low-cost method for the detection of 40 amines relevant to inborn errors of metabolism, in under 60 min, using reverse phase high performance liquid chromatography12
Maximal dietary responsiveness after tetrahydrobiopterin (BH4) in 19 phenylalanine hydroxylase deficiency patients: What super-responders can expect11
Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease11
Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models11
Biallelic variants in the NDUFAF6 cause mitochondrial respiratory complex assembly defects associated with Leigh syndrome in probands11
FBN2 pathogenic mutation in congenital contractural arachnodactyly with severe skeletal manifestations11
X-linked intellectual developmental disorder with onset of neonatal heart failure: A case report and literature review11
Clinical utility of urinary mulberry bodies/cells testing in the diagnosis of Fabry disease10
A 12-month, longitudinal, intervention study examining a tablet protein substitute preparation in the management of tyrosinemia10
Complex response to physiological and drug-induced hepatic heme demand in monoallelic ALAS1 mice10
Patient-reported visual function outcomes agree with visual acuity and ophthalmologist-graded scoring of visual function among patients with long-chain 3-hydroxyacylcoA dehydrogenase deficiency (LCHAD9
Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): Presenting a rescored 4-domain NPC Clinical Severity Scale9
Newborn screening for spinal muscular atrophy in Japan: One year of experience9
Fabry disease caused by the GLA p.Gly183Asp (p.G183D) variant: Clinical profile of a serious phenotype9
Stratification of patients with lysosomal acid lipase deficiency by enzyme activity in dried blood spots9
MAN1B1-CDG: Three new individuals and associated biochemical profiles9
Impact on physical, social, and family functioning of patients with metachromatic leukodystrophy and their family members in Japan: A qualitative study9
Novel homozygous GLDC variant causing late-onset glycine encephalopathy: A case report and updated review of the literature8
The diagnostic rate of inherited metabolic disorders by exome sequencing in a cohort of 547 individuals with developmental disorders8
In depth profiling of dihydrolipoamide dehydrogenase deficiency in primary patients fibroblasts reveals metabolic reprogramming secondary to mitochondrial dysfunction8
Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system8
Five years of newborn screening for Pompe, Mucopolysaccharidosis type I, Gaucher, and Fabry diseases in Oregon7
Quality of life in children living with PKU – a single-center, cross-sectional, observational study from Hungary7
BALB.NCT-Cpox is a unique mouse model of hereditary coproporphyria7
Congenital hypopituitarism due to novel compound heterozygous POU1F1 gene mutation: A case report and review of the literature7
Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase7
CRISPR correction of the Finnish ornithine delta-aminotransferase mutation restores metabolic homeostasis in iPSC from patients with gyrate atrophy7
Starting the conversation on gene therapy for phenylketonuria: Current perspectives of patients, caregivers, and advocates7
Newborn screening and genetic diagnosis of 3-methylcrotonyl-CoA carboxylase deficiency in Quanzhou,China7
A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials6
A novel double GLA gene mutation of W24R and N419D in a patient with cardiac Fabry disease6
The diagnostic journey for patients with late-onset GM2 Gangliosidoses6
Outcomes and genotype correlations in patients with mitochondrial trifunctional protein or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency enrolled in the IBEM-IS database6
Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?6
The biochemical profile and dietary management in S-adenosylhomocysteine hydrolase deficiency6
Medication adherence in Fabry patients treated with migalastat: Real world experience6
The broad spectrum of clinical manifestations observed in three patients with L2 hydroxyglutaric aciduria spans from febrile seizures to complex dystonia6
Critical sample collection delayed? Urine organic acid analysis can still save the day! A new case of HMG-CoA synthase deficiency6
Avalglucosidase alfa in infantile-onset Pompe disease: A snapshot of real-world experience in Italy6
DNAJC12 deficiency: Mild hyperphenylalaninemia and neurological impairment in two siblings6
Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics6
Diagnosis, treatment, and follow-up of a case of Wolman disease with hemophagocytic lymphohistiocytosis6
Impact of classical homocystinuria on health care resource utilization and costs in the United States: A retrospective cohort study6
High incidence of null variants identified from newborn screening of X-linked adrenoleukodystrophy in Taiwan5
Unexplained splenomegaly as a diagnostic marker for a rare but severe disease with an innovative and highly effective new treatment option: A case report5
MPS VII – Extending the classical phenotype5
Diagnosis of atypical myopathy based on organic acid and acylcarnitine profiles and evolution of biomarkers in surviving horses5
LC-MS/MS-based enzyme assay for lysosomal acid lipase using dried blood spots5
A synonymous KCNJ11 variant leading to MODY13: A case report and literature review5
Novel compound heterozygous mutations in LEP responsible for obesity in a Chinese family5
Expression signature of the Leigh syndrome French-Canadian type5
Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan5
Clinical characterization and genetic analysis of transient abnormal myelopoiesis without the down syndrome phenotype5
Hematopoietic cell transplantation for sialidosis type I5
Shared decision making between patients with Fabry disease and physicians in Japan: An online survey5
Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria – Case report5
GBA1 variants in Brazilian Gaucher disease patients5
Association of ZBTB38 gene polymorphism (rs724016) with height and fetal hemoglobin in individuals with sickle cell anemia4
Genetic variations in the IDUA gene in Tunisian MPS I families: Identification of a novel microdeletion disrupting substrate binding and structural insights4
Natural history of inflammation and impaired autophagy in children with Gaucher disease identified by newborn screening4
Relief of nocturnal neuropathic pain with the use of cannabis in a patient with Fabry disease4
Cost analysis of newborn screening for spinal muscular atrophy using digital PCR vs. MLPA4
Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey4
New mutations identified in a case of Glycogenin-1 deficiency4
The metabolic landscape of tetrahydrobiopterin metabolism disorders in the Republic of Ireland4
Neuropsychological endpoints for clinical trials in methylmalonic acidemia and propionic acidemia: A pilot study4
A novel frameshift variant in the SLC2A1 gene causing a mild phenotype of GLUT1 deficiency syndrome: case report4
Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy4
Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series4
Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) – Case series4
Clinical characteristics and interdepartmental collaboration for patients with Anderson–Fabry disease in Shiga Prefecture, Japan4
The mutation spectrum and ethnic distribution of Wilson disease, a review4
Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials4
Characterization of a novel exonic deletion in the GALNS gene causing Morquio A syndrome4
Brain-sparing cord blood transplantation for the borderline stage of adrenoleukodystrophy4
Glutaric aciduria and L-2-hydroxyglutaric aciduria: Clinical and molecular findings of 35 patients from Turkey4
Optimizing clinical outcomes: The journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation4
A study of Iraqi patients with homocysteine remethylation disorders in a tertiary pediatric centre4
Corrigendum to “Long-term follow-up of renal function in patients treated with migalastat for Fabry disease” [Bichet et al., MGM Reports; 28 (2021) 100786]4
Caregiver burden, and parents' perception of disease severity determine health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism4
LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations4
Blepharoptosis in infantile onset Pompe disease: Histological findings and surgical outcomes4
A case report of riboflavin transporter deficiency: A novel heterozygous pathogenic variant in the SLC52A3 gene3
Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype3
A novel cause of emergent hyperammonemia: Cryptococcal fungemia and meningitis3
A child with dilated cardiomyopathy and homozygous splice site variant in FLNC gene3
Classic and Atypical Late Infantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa3
Quantitative muscle ultrasound and electrical impedance myography in late onset Pompe disease: A pilot study of reliability, longitudinal change and correlation with function3
Current status of surviving patients with arginase 1 deficiency in Japan3
Corrigendum to “A new pathogenic POLG variant” [Molecular Genetics and Metabolism Reports 32 (2022) 100890]3
Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program3
Clinical and biochemical phenotypes, genotypes, and long-term outcomes of individuals with galactosemia type I from a single metabolic genetics center in Alberta3
Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice3
Baseline urinary ALA and PBG as criteria for starting pharmacologic prophylactic treatment in acute intermittent porphyria treated with givosiran3
Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease3
Gonadal mosaicism in GNAO1 causing neurodevelopmental disorder with involuntary movements; two additional variants3
An unusually mild case of biotin-thiamine-responsive basal ganglia disease3
Corrigendum to “Expanding the phenotype of RBCK1-associated polyglucosan body myopathy type 1”3
Valine metabolites analysis in ECHS1 deficiency3
Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review3
Navigating social determinants of health barriers in the management of phenylketonuria3
The challenge of adults with phenylketonuria who have been lost to care; a single center's attempt to reach those diagnosed with PKU over 60 years of newborn screening3
Expanded inherited metabolic diseases screening by tandem mass spectrophotometry: The first report from Iran3
Joint replacement risk is markedly increased in alkaptonuria (AKU) in those with prior arthroplasty3
Expanding the phenotype of RBCK1-associated polyglucosan body myopathy type 13
Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice?3
Management of patients with phenylketonuria (PKU) under enzyme replacement therapy: An Italian model (expert opinion)3
Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme3
Dose-intensive therapy (DIT) for infantile Pompe disease: A pilot study3
Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency3
Cardiac manifestations in adult patients with inherited metabolic disease: A single-center experience3
Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review3
Natural history of propionic acidemia in the Amish population3
Breastfeeding practices for infants with inherited metabolic disorders: A survey of registered dietitians in the United States and Canada3
Protective effects of alpha-lipoic acid on hair cell damage in diabetic zebrafish model3
Mutation spectrum of ATP7B gene in pediatric patients with Wilson disease in Vietnam3
0.050836801528931